Plus Therapeutics Inc (PSTV) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Plus Therapeutics Inc (PSTV) has a cash flow conversion efficiency ratio of -0.504x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.55 Million) by net assets ($5.05 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Plus Therapeutics Inc - Cash Flow Conversion Efficiency Trend (1998–2024)
This chart illustrates how Plus Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Plus Therapeutics Inc debt and liabilities for a breakdown of total debt and financial obligations.
Plus Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Plus Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Dr. Hönle AG
F:HNL
|
0.038x |
|
Power Metals Corp
V:PWM
|
-0.018x |
|
Sam Jung Pulp
KO:009770
|
0.010x |
|
Acrivon Therapeutics, Inc. Common Stock
NASDAQ:ACRV
|
-0.096x |
|
BranchOut Food Inc. Common Stock
NASDAQ:BOF
|
-0.347x |
|
Toivo Group Oyj
HE:TOIVO
|
-0.098x |
|
Voksel Electric Tbk
JK:VOKS
|
0.351x |
|
Adisyn Ltd
AU:AI1
|
-0.042x |
Annual Cash Flow Conversion Efficiency for Plus Therapeutics Inc (1998–2024)
The table below shows the annual cash flow conversion efficiency of Plus Therapeutics Inc from 1998 to 2024. For the full company profile with market capitalisation and key ratios, see PSTV market cap.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $-8.95 Million | $-10.55 Million | 1.179x | -87.63% |
| 2023-12-31 | $-1.35 Million | $-12.85 Million | 9.533x | +573.66% |
| 2022-12-31 | $6.45 Million | $-12.97 Million | -2.013x | -112.16% |
| 2021-12-31 | $10.84 Million | $-10.28 Million | -0.949x | +65.91% |
| 2020-12-31 | $3.03 Million | $-8.43 Million | -2.783x | +45.35% |
| 2019-12-31 | $1.16 Million | $-5.91 Million | -5.091x | -122.15% |
| 2018-12-31 | $5.22 Million | $-11.97 Million | -2.292x | -64.35% |
| 2017-12-31 | $13.00 Million | $-18.13 Million | -1.394x | +21.57% |
| 2016-12-31 | $10.99 Million | $-19.53 Million | -1.778x | -6.03% |
| 2015-12-31 | $12.21 Million | $-20.47 Million | -1.677x | -131.53% |
| 2014-12-31 | $-5.70 Million | $-30.33 Million | 5.319x | +148.20% |
| 2013-12-31 | $3.13 Million | $-34.56 Million | -11.035x | -121.27% |
| 2012-12-31 | $6.46 Million | $-32.19 Million | -4.987x | -40.43% |
| 2011-12-31 | $9.95 Million | $-35.32 Million | -3.551x | -244.59% |
| 2010-12-31 | $22.87 Million | $-23.57 Million | -1.031x | -115.84% |
| 2009-12-31 | $-3.66 Million | $-23.81 Million | 6.508x | +50.42% |
| 2008-12-31 | $-7.72 Million | $-33.39 Million | 4.327x | +35.59% |
| 2007-12-31 | $-9.40 Million | $-30.00 Million | 3.191x | +109.33% |
| 2006-12-31 | $-10.81 Million | $-16.48 Million | 1.524x | +762.42% |
| 2005-12-31 | $-6.23 Million | $-1.10 Million | 0.177x | +118.04% |
| 2004-12-31 | $12.83 Million | $-12.57 Million | -0.980x | -101.63% |
| 2003-12-31 | $14.91 Million | $-7.25 Million | -0.486x | -83.45% |
| 2002-12-31 | $26.00 Million | $-6.89 Million | -0.265x | -22.50% |
| 2001-12-31 | $38.49 Million | $-8.32 Million | -0.216x | -257.74% |
| 2000-12-31 | $49.34 Million | $-2.98 Million | -0.060x | -107.28% |
| 1999-12-31 | $-6.15 Million | $-5.11 Million | 0.831x | +105.89% |
| 1998-12-31 | $108.00K | $-1.52 Million | -14.102x | -- |
About Plus Therapeutics Inc
Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. The company's lead radiotherapeutic candidate is REYOBIQ, a patented radiotherapy for patients with central nervous system and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers… Read more